RUNX2 and familial pancreatic carcinoma: Based on our recent results, RUNX2 markedly attenuated the transcriptional as well as pro-apoptotic activity of p53 in response to DNA damage through the complex formation with HDAC6 and p53 [24], and also significantly reduced GEM sensitivity of p53-deficient pancreatic cancer cells through the suppression of TAp63 expression [26].